Accreditation

Program

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Target Audience

Dermatologists, Rheumatologists, Nurses, PAs, Researchers and other healthcare professionals.

 

Course Overview

This activity will address treatment advances for inflammatory skin diseases affecting adults and children. The comprehensive program will cover technological/scientific/medical advances in treatment of Psoriasis; Vitiligo; Atopic Dermatitis; Pemphigus; Blistering Disorders; Chronic Urticaria; Alopecia Areata and other conditions. The program will include world-renowned scientists discussing evolving concepts in treating inflammatory skin diseases as well as the implications in targeted therapeutics.

 

Learning Objectives

After participation in this activity, the learner should be able to:

  1. Identify and analyze new and important studies on inflammatory skin diseases
  2. Apply the most current research on the diagnosis and treatment of inflammatory skin diseases, including psoriasis and eczema
  3. Compare and contrast new targeted therapies for inflammatory skin diseases, and apply them to their practice
  4. Recognize, manage and appropriately treat unusual presentations of inflammatory skin diseases, based on newly developed personalized approaches

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Icahn School of Medicine at Mount Sinai and The Austrian Academy of Sciences.

The Icahn School of Medicine at Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Industry Supported Sessions

Industry

(These sessions are not approved for CME credit.)

 

THURSDAY, NOVEMBER 4, 2021 | 11.00am – 12.30pm

A Treatment Option for Patients with Uncontrolled Moderate-to-Severe Atopic Dermatitis

Symposium supported by Sanofi Genzyme and Regeneron

Faculty: Jonathan Silverberg (Washington, DC, USA)
Learn more about a treatment that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis.

Lunch will be provided. 

 

THURSDAY, NOVEMBER 4, 2021 | 12.45am – 02.15pm

New perspectives on pathogenesis in psoriasis

James Krueger (New York City, USA)

Symposium supported by UCB – Union Chimique Belge

 

 

THURSDAY, NOVEMBER 4, 2021 | 06.00pm – 07.30pm

Illustrating the GaPPs: Understanding the Challenges in Generalized Pustular Psoriasis

Symposium supported by Boehringer Ingelheim Pharma GmbH & Co. KG

Chair: James Krueger (New York City, USA)

06.00pm-06.20pm  Generalized Pustular Psoriasis: A Picture of Disease Mechanisms
James Krueger (New York City, USA)
06.20pm-06.35pm  Generalized Pustular Psoriasis Flares: A Snapshot of Disease Burden
Jeffrey Crowley (USA)
06.35pm–06.55pm Treatment Challenges and Unmet Needs in Generalized Pustular Psoriasis
Bruce Strober (Connecticut, USA)
06.55pm–07.15pm  Coming into Focus: Rationale and Potential for Inhibition of IL-36 in Generalized Pustular Psoriasis
Jeffrey Crowley (California, USA)
07.15pm–07.30pm Live Q&A
James Krueger (New York City, USA)

 

 

FRIDAY, NOVEMBER 5, 2021 | 08.00am – 09.30am

Atopic Dermatitis: The Burden of Disease & a Novel Topical Pathway

Brett King (New Haven, Connecticut, USA)

Symposium supported by Incyte Corporation

 

 

FRIDAY, NOVEMBER 5, 2021 | 12.00pm – 01.30pm

Mechanism of disease of atopic dermatitis and hidradenitis suppurativa and the role of inflammatory cytokine pathways

Symposium supported by Janssen Immunology, Pharmaceutical Companies of Johnson & Johnson

12.00pm-12.05pm  Welcome and introductions
James Krueger (New York City, USA)
12.05pm-12.20pm  Broad perspectives in inflammatory cytokines in skin disorders
James Krueger (New York City, USA)
12.20pm–12.50pm Understanding the current status of AD
Emma Guttman (New York, NY, USA)
12.50pm–01.10pm  Understanding the current status of HS
James Krueger (New York City, USA)
01.10pm–01.30pm  Audience Q&A
Emma Guttman (New York, NY, USA)
James Krueger (New York City, USA)

 

 

FRIDAY, NOVEMBER 5, 2021 | 07.00pm – 08.30pm

Type 2 Inflammation in Skin Barrier and Neuroimmune Axis Dysfunction in Pruritic Dermatoses

Symposium supported by Sanofi Genzyme and Regeneron

07.00pm-07.05pm  Introduction
Lisa Beck (New York City, USA)
07.05pm-07.35pm  The Role of Type 2 Inflammation in Barrier Dysfunction in Pruritic Dermatoses
Lisa Beck (New York City, USA)
07.35pm–08.05pm The Neuroimmune Axis in Itch: Complex Pathophysiology Driving an Important Clinical Symptom
Brian Kim (St. Louis, Missouri, USA)
08.05pm–08.15pm  Managing the Clinical Burden of Itch
Lisa Beck (New York City, USA)
Brian Kim (St. Louis, Missouri, USA)
08.15pm–08.30pm Round table discussion
Lisa Beck (New York City, USA)
Brian Kim (St. Louis, Missouri, USA)

 

 

SATURDAY, NOVEMBER 6, 2021 | 08.00am – 09.30am

Not Just Scratching the Surface: A Look into the Role of IL-13 in the Immunopathogenesis of AD

Symposium supported by Eli Lilly and Company

Moderator: Emma Guttman-Yassky (New York City, USA)

08.00am-08.05am  Welcome and introductions
Emma Guttman-Yassky (New York City, USA)
08.05am-08.20am A Closer Look at IL-13 and its Role in Atopic Dermatitis
Emma Guttman-Yassky (New York City, USA)
08.20am-08.35am A Deep Dive into Type 2 Inflammation and Chronic Itch
Gil Yosipovitch (Miami, Florida, USA)
08.35am-08.50am IL-13 and Neuronal Itch
Ethan Lerner (Boston, Massachusetts, USA)
08.50am-09.05am Cytokine vs. Receptor Targeting: Lessons from Psoriasis
James Krueger (New York City, USA)
09.05am-09.15am Panel Discussion
09.15am-09.25am Audience Q & A
09.25am-09.30am Summary and Concluding Remarks
Emma Guttman-Yassky (New York City, USA)

 


SATURDAY, NOVEMBER 6, 2021 | 12.30pm – 02.00pm

New insights into skin phenotypes in atopic dermatitis – are we modifying disease?

Symposium supported by LEO Pharma

Chairs:

  • Emma Guttman-Yassky (New York City, USA)
  • Kristian Reich (Hamburg, Germany)
12.30pm-12.35pm  Welcome and setting the scene
Emma Guttman-Yassky (New York City, USA)
12.35pm-12.50pm Can we talk about disease modification in AD?
Kristian Reich (Hamburg, Germany)
12.50pm-01.05pm  Shifting the molecular phenotype in AD using targeted treatments
Emma Guttman-Yassky (New York City, USA)
01.05pm-01.20pm  The role of acquired versus innate immunity in AD
Kenji Kabashima (Kyoto, Japan)
01-20pm-01.35pm  The role of tissue-resident memory T cells, regulatory T cells and the inflammatory phenotype in AD
Patrick Brunner (New York City, USA)
01.35pm-02.00pm  Are we modifying disease with emerging treatments?
Panel discussion

 

 

SATURDAY, NOVEMBER 6, 2021 | 04.30pm – 06.00pm

The AD Revolution

Symposium supported by AbbVie

Chair: Emma Guttman-Yassky (New York City, USA)

04.40om-04.50pm  Overview of the symposium
Objective/Agenda
04.50pm-05.10pm  AD care and the HCP/Patient relationship
Shawn Kwatra
05.10pm-05.30pm  AD as a multidimensional disease – What we know and what we don’t
Emma Guttman-Yassky (New York City, USA)
05.30pm-05.50pm  The AD management future – Pushing the efficacy boundaries
Shawn Kwatra
05.50pm-06.00pm  Panel discussion & close

 

Accreditation

Uncategorized

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Target Audience

Dermatologists, Rheumatologists, Nurses, PAs, Researchers and other healthcare professionals.

 

Course Overview

This activity will address treatment advances for inflammatory skin diseases affecting adults and children. The comprehensive program will cover technological/scientific/medical advances in treatment of Psoriasis; Vitiligo; Atopic Dermatitis; Pemphigus; Blistering Disorders; Chronic Urticaria; Alopecia Areata and other conditions. The program will include world-renowned scientists discussing evolving concepts in treating inflammatory skin diseases as well as the implications in targeted therapeutics.

 

Learning Objectives

After participation in this activity, the learner should be able to:

  1. Identify and analyze new and important studies on inflammatory skin diseases
  2. Apply the most current research on the diagnosis and treatment of inflammatory skin diseases, including psoriasis and eczema
  3. Compare and contrast new targeted therapies for inflammatory skin diseases, and apply them to their practice
  4. Recognize, manage and appropriately treat unusual presentations of inflammatory skin diseases, based on newly developed personalized approaches

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Icahn School of Medicine at Mount Sinai and The Austrian Academy of Sciences.

The Icahn School of Medicine at Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

 

Credit Designation

Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Organizing Committee

General

James G. Krueger, M.D., Ph.D.
Director, Milstein Medical Research Program
Senior Attending Physician
D. Martin Carter Professor in Clinical Investigation
Laboratory of Investigative Dermatology
The Rockefeller University, New York City, USA

Emma Guttman-Yassky, M.D., Ph.D.
Waldman Professor and System Chair
The Kimberly and Eric J. Waldman Department of Dermatology Director,
Center of Excellence in Eczema Director, Laboratory of Inflammatory
Skin Diseases Icahn School of Medicine at Mount Sinai, New York City, USA

Georg Stingl, M.D.
Professor emeritus
Department of Dermatology
Medical University of Vienna, Austria

Patrick M. Brunner, M.D., M.Sc.
Associate Professor
Department of Dermatology
Medical University of Vienna, Austria

General Information

General

Over the last few decades, biomedical research has unraveled a plethora of pathophysiological steps putatively important for human disease development. But it was only in the last few years that a broader translation from basic research efforts to clinical medicine has indeed occurred. This was largely made possible by the close cooperation of basic researchers and clinical investigators, aiming at the development of truly effective therapeutics. Inflammatory skin diseases such as psoriasis and atopic dermatitis serve as an example of this successful bench-to-bedside approach. Currently, more and more therapies are approved as a result of this scientific approach, and many more are on their way.

Nevertheless, a stand-alone meeting in which inflammatory skin diseases and the translational revolution that we are currently experiencing take center stage has been lacking. After three very successful meetings in Vienna in 2014 and 2018 and in New York City in 2016, we have again taken upon the task of organizing such an important meeting in order to continue this path of therapeutic revolution and extend to other inflammatory skin diseases. We want to discuss new concepts and new developments in the field of inflammatory skin diseases and to devise and explore new therapeutic strategies. For the last two meetings, we had been able to attract true leaders in their fields, and we had approximately 600 participants from all over the world at the 2018 meeting in Vienna. We have now established this conference on an every two-year basis, with the next meeting taking place in New York City, USA, November 3-6, 2021.